Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 78
Filtrar
1.
Actas Dermosifiliogr ; 2024 Mar 06.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-38452894

RESUMO

BACKGROUND: There is a need for epidemiological and incidence data on the occurrence of basal cell carcinoma (BCC) in Spain. OBJECTIVES: Our study was designed to retrospectively retrieve cases from our computer databases from 2010 through 2016 to provide updated data on the actual incidence of BCC in Valencia, eastern Spain. MATERIAL AND METHODS: This was an epidemiological study on basal cell carcinoma conducted in Valencia, eastern Spain. We analyzed a total of 2171 patients and 4047 tumors, and gathered data to estimate the actual incidence of BBC in our region. RESULTS AND CONCLUSIONS: Our study confirmed that the incidence of BCC is much higher than previously reported. We calculated a crude incidence of 410.38 BCCs/100 000 person-years, an adjusted rate for the European population of 256.98 BCCs/100 000 person-years, and an adjusted rate for the world population of 196.26 BCCs/100 000 person-years. Risk is up to 29.49% higher for men (464.07 cases/100 000 person-years vs 358.40 cases/100 000 person-years for women). Incidence also increases by an annual 3.91% (a significantly higher annual incidence of 8.28% in women vs a 0.92% annual incidence in men). Overall, the lifetime risk for developing a BCC is 5.8% (5.02% in women and 7% in men).

11.
Actas dermo-sifiliogr. (Ed. impr.) ; 111(3): 249-253, abr. 2020. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-191528

RESUMO

ANTECEDENTES: La asociación entre los inhibidores de la dipeptidil peptidasa 4 (iDPP-4) y el penfigoide ampolloso (PA) se ha demostrado en varios estudios. El objetivo principal de este estudio era estimar el uso del tratamiento con iDPP-4i en pacientes diagnosticados de PA en nuestro entorno. MATERIAL Y MÉTODOS: Seleccionamos pacientes diagnosticados histológicamente de PA en nuestro departamento entre octubre de 2015 y octubre de 2018. Realizamos una revisión retrospectiva para evaluar los datos clínicos-epidemiológicos y los patrones de inmunofluorescencia directa (IFD). RESULTADOS: De los 70 pacientes diagnosticados con PA durante el período de estudio, el 50% eran diabéticos y el 88,57% de ellos estaban siendo tratados con un iDPP-4 en el momento del diagnóstico de PA. El iDPP-4 más frecuente era la linagliptina (utilizada en el 18,6% de los pacientes), seguida de la vildagliptina (el 17,1%). La mediana de tiempo de latencia entre el inicio del tratamiento con iDPP-4 y el diagnóstico de PA fue de 27,5 meses, siendo de 16 meses para la linagliptina y 39 meses para la vildagliptina (log Rank < 0,01). La IFD fue negativaUn resultado negativo de DIF fue significativamente más común en pacientes que no fueron tratados con un DPP-4i. El patrón DIF más fuertemente (y significativamente) asociado con el tratamiento con DPP-4i fueron los depósitos lineales de inmunoglobulina G a lo largo de la unión dermoepidérmica. El tratamiento con DPP-4i se retiró en el 87% de los pacientes y el 96% de ellos logró una respuesta completa. CONCLUSIÓN: El tratamiento con DPP-4i es muy común en pacientes con BP en nuestro entorno. El período de latencia entre el inicio del tratamiento y el inicio de la PA parece ser más corto con linagliptina que con otros tipos de gliptinas. Los pacientes que reciben tratamiento con DPP-4i pueden mostrar patrones DIF diferentes a los que no reciben tratamiento


BACKGROUND: The association between dipeptidyl peptidase 4 inhibitors (DPP-4i) and bullous pemphigoid (BP) has been demonstrated in several studies. The main aim of this study was to estimate the use of DPP-4i treatment in patients diagnosed with BP in our setting. METHODS: We selected patients histologically diagnosed with BP in our department between October 2015 and October 2018 and performed a retrospective chart review to assess clinical and epidemiological data and direct immunofluorescence (DIF) patterns. RESULTS: Of the 70 patients diagnosed with BP during the study period, 50% were diabetic and 88.57% of these were being treated with a DPP-4i when diagnosed with BP. The most common DPP-4i was linagliptin (used in 18.6% of patients), followed by vildagliptin (17.1%). The median latency period between initiation of DPP-4i treatment and diagnosis of BP was 27.5 months for all treatments, 16 months for linagliptin, and 39 months for vildagliptin (log rank < 0.01). A negative DIF result was significantly more common in patients not being treated with a DPP-4i. The DIF pattern most strongly (and significantly) associated with DPP-4i treatment was linear immunoglobulin G deposits along the dermal-epidermal junction. DPP-4i treatment was withdrawn in 87% of patients and 96% of these achieved a complete response. CONCLUSIONS: DPP-4i treatment is very common in patients with BP in our setting. The latency period between start of treatment and onset of BP seems to be shorter with linagliptin than with other types of gliptins. Patients receiving DPP-4i treatment may show different DIF patterns to those not receiving treatment


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Penfigoide Bolhoso/epidemiologia , Técnica Direta de Fluorescência para Anticorpo/normas , Penfigoide Bolhoso/induzido quimicamente , Estudos Retrospectivos , Inibidores da Dipeptidil Peptidase IV/administração & dosagem
12.
Actas dermo-sifiliogr. (Ed. impr.) ; 111(2): 135-142, mar. 2020. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-191503

RESUMO

INTRODUCCIÓN: La sífilis es una infección de transmisión sexual (ITS) producida por el Treponema pallidum subespecie pallidum, bacteria difícil de cultivar por lo que se requieren técnicas serológicas para su diagnóstico. La aparición de nuevas pruebas treponémicas (PT) automatizadas ha supuesto un cambio en el algoritmo diagnóstico de la sífilis, el cual tradicionalmente se iniciaba con una prueba no treponémica (PNT). Presentamos 15 casos de sífilis primarias detectadas gracias a la utilización de las nuevas PT automatizadas y realizamos una revisión de las técnicas microbiológicas en el diagnóstico de la sífilis precoz. MATERIAL Y MÉTODOS: Se recogieron todos los casos de sífilis diagnosticados en nuestro servicio desde enero de 2013 hasta septiembre de 2018. Se seleccionaron los pacientes con PNT negativas, Rapid Plasma Reagin (RPR) en particular. RESULTADOS: De un total de 158 pacientes diagnosticados de sífilis en este periodo, 15 presentaron PNT (RPR) negativas y de estos 15, todos excepto uno presentaron PT positivas. Catorce casos eran varones, con un rango de edad desde 22 a 60 años. Además, a 8 pacientes se les realizó reacción en cadena de la polimerasa (PCR) del exudado de la úlcera, siendo en todos ellos positiva. Los 15 pacientes fueron tratados con una dosis única de penicilina G benzatina 2,4 MUI. CONCLUSIÓN: resaltamos la utilidad de las nuevas técnicas serológicas automatizadas, Chemiluminiscence Inmunoassay (CLIA) y Automated Treponema Pallidum Enzime linked Inmunoassay (EIA) y apoyamos su implantación como pruebas de screening en el diagnóstico de sífilis, dado su sensibilidad diagnóstica, su rapidez y su bajo coste


BACKGROUND: Syphilis is a sexually transmitted infection caused by Treponema pallidum, subspecies pallidum. As these bacteria are difficult to culture, syphilis must be diagnosed by serologic testing. The introduction of automated treponemal tests has led to changes in the traditional diagnostic algorithm for syphilis, which began with a nontreponemal test. We present 15 cases of primary syphilis detected using these new tools and review the microbiologic techniques used for the diagnosis of early syphilis. MATERIAL AND METHODS: We examined all cases of syphilis diagnosed in our department between January 2013 and September 2018 and selected patients with negative nontreponemal (rapid plasma reagin [RPR]) tests. RESULTS: Of the 158 patients diagnosed with syphilis during the study period, 15 had a negative RPR test, and 14 of them had a positive treponemal test. Fourteen of the patients were men and ages ranged from 22 to 60 years. Polymerase chain reaction was used to detect T pallidum in the lesion exudate from 8 patients and was positive in all cases. The 15 patients were treated with a single injection of 2.4 million units of benzathine penicillin G. CONCLUSIÓN: Chemiluminescence immunoassays and T pallidum automated enzyme-linked immunoassays are useful in the diagnosis of early syphilis, and we believe that they should be adopted as screening tools given their diagnostic sensitivity, speed, and low cost


Assuntos
Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Sorodiagnóstico da Sífilis/métodos , Sífilis/diagnóstico , Sorodiagnóstico da Sífilis , Treponema pallidum/isolamento & purificação , Microscopia/métodos , Técnicas Microbiológicas/métodos , Reação em Cadeia da Polimerase
13.
Actas dermo-sifiliogr. (Ed. impr.) ; 111(1): 53-58, ene.-feb. 2020. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-191485

RESUMO

INTRODUCCIÓN Y OBJETIVO: Se ha constatado un cambio en la epidemiología del herpes genital en los últimos años con un aumento de la incidencia del virus herpes (VHS) tipo 1. El objetivo de nuestro estudio es analizar las características clínico-epidemiológicas de los pacientes diagnosticados de un herpes genital. MATERIAL Y MÉTODOS: Se diseñó un estudio observacional retrospectivo donde se incluyeron todos los pacientes diagnosticados de herpes genital entre enero de 2016 y enero de 2019 en una Unidad de Infecciones de Transmisión Sexual (ITS) en Valencia, España. RESULTADOS: Se diagnosticaron 895 ITS, de las cuales 126 fueron un herpes genital (14%), 68 (54%) en mujeres y 58 (46%) en hombres. En 110 de ellos (87,3%) se confirmó el herpes genital por la detección de ADN viral por técnicas moleculares. Se diagnosticaron 52 casos de VHS tipo 1 (47,3%) y 58 casos de VHS tipo 2 (52,7%). En el 69,5% de los hombres se detectó el VHS tipo 2, mientras que en el 59,3% de las mujeres se detectó el VHS tipo 1. La edad media de las mujeres diagnosticadas de VHS tipo 1 fue de 26 años, mientras que la de las mujeres diagnosticadas de VHS tipo 2 fue de 34 años (p = 0,015). Las recurrencias de las lesiones en los pacientes con VHS tipo 1 y VHS tipo 2 fue del 13% y del 40%, respectivamente. CONCLUSIÓN: Destacamos un aumento de la prevalencia del VHS tipo 1 en nuestro medio como agente causante de herpes genital, especialmente en mujeres jóvenes. Esto tiene un valor pronóstico importante dado el menor riesgo de recurrencias que tiene


INTRODUCTION AND OBJECTIVE: The epidemiology of genital herpes has changed in recent years with an increase in the incidence of herpes simplex virus type 1 (HSV-1) infection. The aim of this study was to analyze the clinical and epidemiological characteristics of patients diagnosed with genital herpes. MATERIAL AND METHODS: A retrospective observational study was designed. All patients diagnosed with genital herpes between January 2016 and January 2019 in a Sexually Transmitted Infections Unit (ITS) in Valencia, Spain, were included. RESULTS: We identified 895 STI diagnoses. Of these, 126 (14%) were genital herpes; 68 (54%) of these cases were in women and 58 (46%) in men. Diagnosis was confirmed by molecular detection of HSV DNA in 110 cases (87.3%). Of these, 52 were cases of HSV-1 infection (47.3%) and 58 were HSV-2 infection (52.7%). HSV-2 was more common in men (69.5%), while HSV-1 was more common in women (59.3%). In the subgroup of women, mean age at diagnosis was 26 years for HSV-1 and 34 years for HSV-2 (P = .015). Recurrent genital herpes rates were 13% for HSV-1 and 40% for HSV-2. CONCLUSIONS: There has been an increase in the number of cases of genital herpes caused by HSV-1 in our setting, with young women in particular being affected. This has important prognostic implications because genital herpes caused by HSV-1 is less likely to recur


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Herpes Genital/epidemiologia , Herpes Genital/diagnóstico , Herpesvirus Humano 2/isolamento & purificação , Herpesvirus Humano 1/isolamento & purificação , Estudos Retrospectivos , Espanha/epidemiologia , Herpes Genital/microbiologia , DNA Viral/análise , Homossexualidade Masculina/estatística & dados numéricos , Reação em Cadeia da Polimerase/métodos
14.
Actas Dermosifiliogr (Engl Ed) ; 111(2): 135-142, 2020 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31831159

RESUMO

BACKGROUND: Syphilis is a sexually transmitted infection caused by Treponema pallidum, subspecies pallidum. As these bacteria are difficult to culture, syphilis must be diagnosed by serologic testing. The introduction of automated treponemal tests has led to changes in the traditional diagnostic algorithm for syphilis, which began with a nontreponemal test. We present 15 cases of primary syphilis detected using these new tools and review the microbiologic techniques used for the diagnosis of early syphilis. MATERIAL AND METHODS: We examined all cases of syphilis diagnosed in our department between January 2013 and September 2018 and selected patients with negative nontreponemal (rapid plasma reagin [RPR]) tests. RESULTS: Of the 158 patients diagnosed with syphilis during the study period, 15 had a negative RPR test, and 14 of them had a positive treponemal test. Fourteen of the patients were men and ages ranged from 22 to 60 years. Polymerase chain reaction was used to detect T pallidum in the lesion exudate from 8 patients and was positive in all cases. The 15 patients were treated with a single injection of 2.4 million units of benzathine penicillin G. CONCLUSION: Chemiluminescence immunoassays and T pallidum automated enzyme-linked immunoassays are useful in the diagnosis of early syphilis, and we believe that they should be adopted as screening tools given their diagnostic sensitivity, speed, and low cost.


Assuntos
Sorodiagnóstico da Sífilis/métodos , Sífilis/diagnóstico , Treponema pallidum/isolamento & purificação , Adulto , ELISPOT/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Sífilis/patologia , Treponema pallidum/imunologia , Adulto Jovem
15.
Actas Dermosifiliogr (Engl Ed) ; 111(3): 249-253, 2020 Apr.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31864538

RESUMO

BACKGROUND: The association between dipeptidyl peptidase 4 inhibitors (DPP-4i) and bullous pemphigoid (BP) has been demonstrated in several studies. The main aim of this study was to estimate the use of DPP-4i treatment in patients diagnosed with BP in our setting. METHODS: We selected patients histologically diagnosed with BP in our department between October 2015 and October 2018 and performed a retrospective chart review to assess clinical and epidemiological data and direct immunofluorescence (DIF) patterns. RESULTS: Of the 70 patients diagnosed with BP during the study period, 50% were diabetic and 88.57% of these were being treated with a DPP-4i when diagnosed with BP. The most common DPP-4i was linagliptin (used in 18.6% of patients), followed by vildagliptin (17.1%). The median latency period between initiation of DPP-4i treatment and diagnosis of BP was 27.5 months for all treatments, 16 months for linagliptin, and 39 months for vildagliptin (log rank < 0.01). A negative DIF result was significantly more common in patients not being treated with a DPP-4i. The DIF pattern most strongly (and significantly) associated with DPP-4i treatment was linear immunoglobulin G deposits along the dermal-epidermal junction. DPP-4i treatment was withdrawn in 87% of patients and 96% of these achieved a complete response. CONCLUSIONS: DPP-4i treatment is very common in patients with BP in our setting. The latency period between start of treatment and onset of BP seems to be shorter with linagliptin than with other types of gliptins. Patients receiving DPP-4i treatment may show different DIF patterns to those not receiving treatment.


Assuntos
Inibidores da Dipeptidil Peptidase IV , Penfigoide Bolhoso , Inibidores da Dipeptidil Peptidase IV/efeitos adversos , Humanos , Linagliptina/efeitos adversos , Penfigoide Bolhoso/induzido quimicamente , Estudos Retrospectivos , Vildagliptina
20.
Actas dermo-sifiliogr. (Ed. impr.) ; 109(4): 340-345, mayo 2018.
Artigo em Espanhol | IBECS | ID: ibc-175509

RESUMO

INTRODUCCIÓN: Actualmente el riesgo de cáncer cutáneo asociado a la fototerapia UVB de banda estrecha no se conoce con precisión. Aunque existe un riesgo demostrado en estudios experimentales los estudios en la práctica clínica no han encontrado un aumento en la frecuencia de neoplasias en los pacientes tratados con esta modalidad de fototerapia. El objetivo de nuestro trabajo es determinar la incidencia de fotocarcinogénesis de la fototerapia UVB-BE en un hospital terciario del área mediterránea. MATERIAL Y MÉTODO: Se ha realizado un estudio observacional retrospectivo selecionando 474 pacientes que habían recibido tratamiento con UVB-BE de cuerpo completo entre 2002 y 2016 realizando un seguimiento en la historia clínica revisando los pacientes que habían sido diagnosticados de CCNM. Se calculó la densidad de incidencia bruta y ajustada y se comparó con la frecuencia en la población normal de un area geográfica similar. RESULTADOS: De los 474 pacientes estudiados, 193 eran hombres (40,7%) y 281 mujeres (59,3%). El tiempo medio de seguimiento fue de 5,8+-3 años. La prevalencia de neoplasias al final del periodo de estudio fue del 1,9% La densidad de incidencia ajustada fue de 108,3 casos / 100.000 pacientes tratados - año. La relación estandarizada de riesgo en comparación con la población general fue de 1,9 sin llegar a ser estadísticamente significativa. El número necesario a tratar para producir un caso de cáncer cutáneo fue de 1.900 pacientes. CONCLUSIÓN: La fototerapia UVB-BE no parece asociarse con un riesgo aumentado de cáncer cutáneo no melanoma en los pacientes tratados con esta modalidad de tratamiento


BACKGROUND: The risk of skin cancer in patients treated with narrowband (NB) UV-B phototherapy is not well understood. Although experimental studies have shown that there is a risk, clinical studies have not detected an increased incidence of cancer following treatment. The aim of this study was to determine the incidence of nonmelanoma skin cancer (NMSC) in patients treated with NB UV-B phototherapy at a tertiary care hospital in the Mediterranean area. MATERIAL AND METHODS: We conducted a retrospective chart review of 474 patients who received whole-body NB UV-B phototherapy at our hospital between 2002 and 2016 and identified those diagnosed with NMSC during follow-up. We calculated the corresponding crude and standardized incidence rates and compared these with rates in the general population in a similar geographic area. RESULTS: Of the 474 patients, 193 (40.7%) were men and 281 (59.3%) were women. The mean (SD) follow-up period was 5.8 (3) years. The prevalence of NMSC at the end of the study period was 1.9% and the standardized incidence was 108.3 cases per 100 000 patient-years. The SIR of 1.9 in the study group was not significantly different from that of the general population. The number of patients who needed to be treated with NB UV-B phototherapy for 1 case of NMSC to occur was 1900. CONCLUSION: NB UV-B phototherapy does not appear to be associated with an increased risk of NMSC


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Estudo Observacional , Neoplasias Induzidas por Radiação/etiologia , Neoplasias Cutâneas/etiologia , Terapia Ultravioleta/efeitos adversos , Incidência , Neoplasias Induzidas por Radiação/epidemiologia , Estudos Retrospectivos , Risco , Neoplasias Cutâneas/epidemiologia , Espanha/epidemiologia , Centros de Atenção Terciária/estatística & dados numéricos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...